MRSA from Levinson's microbiology 18th edition
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
I now have thorough content from two core microbiology textbooks. Let me compile the complete answer.
Note: Levinson's Review of Medical Microbiology & Immunology (18th ed.) is not in the library's collection. The content below is drawn from the two closest equivalents — Sherris & Ryan's Medical Microbiology, 8th ed. and Jawetz, Melnick & Adelberg's Medical Microbiology, 28th ed. — both of which cover MRSA in a style and depth virtually identical to Levinson's.
Methicillin-Resistant Staphylococcus aureus (MRSA)
1. Background & Epidemiology
- When penicillin was introduced post-WWII, virtually all S. aureus strains were susceptible. Selective pressure led to the emergence of penicillinase-producing strains (now >90% of clinical isolates), which were then overcome by methicillin (a penicillinase-resistant penicillin).
- MRSA subsequently emerged — strains resistant to methicillin, oxacillin, nafcillin, and all cephalosporins.
- MRSA rates show great geographic variation, but rates of ≥50% among S. aureus isolates are now common in many settings, particularly ICUs.
2. Mechanism of Resistance
β-Lactam Resistance (mecA gene)
| Feature | Detail |
|---|---|
| Genetic basis | mecA (or mecC) gene, located on a mobile chromosomal element — the Staphylococcal Cassette Chromosome mec (SCCmec) |
| Protein product | PBP2a (also called PBP2') — an altered penicillin-binding protein / peptidoglycan transpeptidase |
| Mechanism | PBP2a has markedly reduced affinity for β-lactam antibiotics but retains full enzymatic function (cross-linking peptidoglycan), allowing cell wall synthesis to continue in the presence of β-lactams |
| Cross-resistance | Resistant to all β-lactams: penicillins, penicillinase-resistant penicillins (oxacillin, nafcillin), cephalosporins, carbapenems — except ceftaroline (a 5th-gen cephalosporin that retains MRSA activity) |
This is distinct from β-lactamase-mediated resistance (plasmid-encoded, opens the β-lactam ring). MRSA resistance is chromosomally encoded and target-based.
— Sherris & Ryan's Medical Microbiology, 8th ed., p. 983–984; Jawetz, Melnick & Adelberg's, 28th ed.
3. SCCmec Types: HA-MRSA vs. CA-MRSA vs. LA-MRSA
| Type | Association | Features |
|---|---|---|
| Types I, II, III, VI, VIII | Hospital-acquired MRSA (HA-MRSA) | Larger SCCmec elements; carry multiple additional resistance genes → multidrug-resistant "superbugs" |
| Type IV | Community-acquired MRSA (CA-MRSA) | Smaller SCCmec element; less multidrug resistance; more transmissible; responsible for outbreaks in the US and Europe |
| Types IX, X | Livestock-associated MRSA (LA-MRSA) | Type IX contains mecC; linked to animal reservoirs |
— Jawetz, Melnick & Adelberg's, 28th ed.
4. CA-MRSA: Distinctive Features
- USA300 is the dominant CA-MRSA clone in the United States.
- CA-MRSA causes aggressive skin and soft tissue infections and a particularly severe necrotizing pneumonia.
- The virulence of CA-MRSA is largely attributed to Panton-Valentine Leukocidin (PVL):
- A pore-forming cytotoxin active against neutrophils and platelets
- Causes tissue necrosis and leukocyte destruction
- Present in almost all USA300 isolates (CA-MRSA), but rare in HA-MRSA
Key concept: Virulence and resistance are separate, genetically unlinked properties. MRSA's epidemiologic advantage comes from resistance; enhanced pathogenicity in CA-MRSA requires additional virulence factors like PVL.
— Sherris & Ryan's Medical Microbiology, 8th ed., p. 984
5. Vancomycin Resistance Spectrum: VISA and VRSA
| Strain | Vancomycin MIC | Mechanism |
|---|---|---|
| Susceptible | ≤2 μg/mL | — |
| VISA (Vancomycin-Intermediate S. aureus) | 4–8 μg/mL | Increased cell wall synthesis; thickened cell wall traps vancomycin before it reaches its target; no vanA gene |
| VRSA (Vancomycin-Resistant S. aureus) | ≥16 μg/mL | Acquired vanA gene from enterococci (horizontal transfer), combined with mecA; first isolated in US in 2002 |
- VISA typically arises after prolonged vancomycin therapy and usually has treatment failure as a clinical harbinger.
- VISA strains are usually susceptible to oxazolidinones (linezolid) and quinupristin-dalfopristin.
— Jawetz, Melnick & Adelberg's, 28th ed.
6. Laboratory Detection
- Oxacillin/nafcillin susceptibility testing is the standard phenotypic test — resistance to oxacillin implies resistance to nafcillin and all cephalosporins.
- mecA gene detection (molecular PCR) is available but poses an interpretive challenge: mecA may be present in phenotypically susceptible isolates, and such strains may revert to the MRSA phenotype during treatment → still considered resistant.
- Cefoxitin disk diffusion is often used as a surrogate for mecA detection.
— Sherris & Ryan's Medical Microbiology, 8th ed., p. 984
7. Treatment
Drug selection depends on: (1) presence of MRSA, (2) severity of infection, (3) patient β-lactam hypersensitivity history.
| Infection Type | Preferred Agents |
|---|---|
| Deep-seated (endocarditis, osteomyelitis, bacteremia, pneumonia) | Vancomycin (IV), Daptomycin |
| Superficial skin and soft tissue | TMP-SMX, macrolides, tetracyclines (doxycycline), clindamycin |
| MRSA-active cephalosporin | Ceftaroline (5th-gen) — only β-lactam with MRSA activity |
| Multidrug-resistant / VISA | Linezolid, quinupristin-dalfopristin |
Empiric therapy in suspected staphylococcal infection often starts with vancomycin (covers both MRSA and MSSA). Once MRSA is excluded, a more specific β-lactam (e.g., oxacillin) is substituted.
— Sherris & Ryan's Medical Microbiology, 8th ed., p. 985
8. Prevention
| Measure | Detail |
|---|---|
| Skin decolonization | Chlorhexidine or hexachlorophene soaps |
| Nasal decolonization | Topical mupirocin (nasal cream) ± oral rifampin or ciprofloxacin (for outbreak control) |
| Surgical chemoprophylaxis | Oxacillin, cefazolin, or vancomycin during high-risk surgery (hip/cardiac valve replacement) |
| Contact isolation | For hospitalized MRSA-positive patients |
| MRSA bundle (hospital) | Includes nasal PCR screening on admission/transfer/discharge, contact isolation, standardized decolonization protocols |
Summary Table
| Feature | Detail |
|---|---|
| Organism | Staphylococcus aureus |
| Resistance gene | mecA (or mecC) → encodes PBP2a |
| Mobile element | SCCmec (staphylococcal cassette chromosome mec) |
| β-Lactam cross-resistance | All β-lactams except ceftaroline |
| HA-MRSA | SCCmec I/II/III; multidrug resistant |
| CA-MRSA | SCCmec IV; less resistant; PVL-positive (USA300) |
| VISA | Thickened cell wall; MIC 4–8 μg/mL; no vanA |
| VRSA | Acquired vanA from enterococci; MIC ≥16 μg/mL |
| Treatment (severe) | Vancomycin, daptomycin |
| Treatment (mild/skin) | TMP-SMX, doxycycline, clindamycin |
Make a ppt and mention references
Reading File
Reading File
Reading File
Running Command
Running Command
Writing File
Running Command
The presentation is ready. Download it here:
MRSA Microbiology
Presentation · PPTX
What's inside (10 slides, dark navy/red theme):
| Slide | Content |
|---|---|
| 1 | Title slide |
| 2 | Definition & Overview |
| 3 | Mechanism of Resistance (mecA → PBP2a, vs. β-lactamase) |
| 4 | HA-MRSA vs CA-MRSA vs LA-MRSA (SCCmec types) |
| 5 | PVL & CA-MRSA Virulence |
| 6 | Vancomycin Resistance — VISA & VRSA |
| 7 | Treatment (severe vs mild, empiric strategy) |
| 8 | Prevention & Infection Control (MRSA bundle) |
| 9 | Summary table |
| 10 | References (7 citations incl. Sherris & Ryan, Jawetz, IDSA guidelines) |
This is a shared conversation. Sign in to Orris to start your own chat.